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The frog skin-derived peptide Temporin 1Tb (TB) has gained increasing attention
as novel antimicrobial agent for the treatment of antibiotic-resistant and/or biofilm-
mediated infections. Nevertheless, such a peptide possesses a preferential spectrum
of action against Gram-positive bacteria. In order to improve the therapeutic potential
of TB, the present study evaluated the antibacterial and antibiofilm activities of two TB
analogs against medically relevant bacterial species. Of the two analogs, TB_KKG6A
has been previously described in the literature, while TB_L1FK is a new analog
designed by us through statistical-based computational strategies. Both TB analogs
displayed a faster and stronger bactericidal activity than the parental peptide, especially
against Gram-negative bacteria in planktonic form. Differently from the parental peptide,
TB_KKG6A and TB_L1FK were able to inhibit the formation of Staphylococcus aureus
biofilms by more than 50% at 12 µM, while only TB_KKG6A prevented the formation
of Pseudomonas aeruginosa biofilms at 24 µM. A marked antibiofilm activity against
preformed biofilms of both bacterial species was observed for the two TB analogs when
used in combination with EDTA. Analysis of synergism at the cellular level suggested
that the antibiofilm activity exerted by the peptide-EDTA combinations against mature
biofilms might be due mainly to a disaggregating effect on the extracellular matrix in
the case of S. aureus, and to a direct activity on biofilm-embedded cells in the case of
P. aeruginosa. Both analogs displayed a low hemolytic effect at the active concentrations
and, overall, TB_L1FK resulted less cytotoxic toward mammalian cells. Collectively, the
results obtained demonstrated that subtle changes in the primary sequence of TB may
provide TB analogs that, used alone or in combination with adjuvant molecules such as
EDTA, exhibit promising features against both planktonic and biofilm cells of medically
relevant bacteria.
Keywords: Temporin 1Tb, analogs, biofilm, peptide design, antimicrobial peptides
Grassi et al. TB Analogs with Improved Activity
INTRODUCTION
The development and rapid spread of antibiotic resistance
among clinically relevant bacteria has dramatically reduced
the effectiveness of antimicrobial therapies, thereby emerging
as a major challenge for modern medicine (Boucher et al.,
2009; Högberg et al., 2010). The ability of bacteria to form
biofilms, architecturally complex cell aggregates embedded in an
extracellular polymeric substance (EPS) and intrinsically tolerant
to conventional antibiotics, further exacerbates the problem of
bacterial resistance and is responsible for the persistence and
chronicization of many types of infections (Costerton et al.,
1999). Biofilms can be up to 1,000-fold more resistant to
antimicrobial agents than their planktonic counterparts thanks to
unique phenotypic and metabolic properties that allow them to
implement resistance mechanisms at the community level. These
include the presence of the EPS that reduces the diffusion of
antibacterial compounds into the biofilm structure, the overall
low growth rate of biofilm-forming bacteria, the presence of
subpopulations of cells in a dormant state (“persisters”), and the
cell proximity that promotes the horizontal gene transfer and
the acquisition of mobile genetic elements encoding resistance
(Høiby et al., 2010; Batoni et al., 2016a).
Over the last years, antimicrobial peptides (AMPs) have
gained increasing attention as novel antimicrobial drugs for the
control of infections sustained by antibiotic-resistant bacteria
and/or bacterial biofilms. Due to their mainmechanism of action,
which involves the disruption of cell membrane integrity, AMPs
exert a strong antimicrobial activity against a broad spectrum
of pathogens, including multidrug-resistant bacterial strains,
and generally prove a low frequency in inducing resistance
(Zasloff, 2002). Moreover, they are able to target metabolically
inactive and even non-growing cells that are commonly found
within microbial biofilms (Di Luca et al., 2014; Batoni et al.,
2016a). To date, over 2500 AMPs have been identified and
evaluated for their antimicrobial activity (Antimicrobial Peptide
Database: aps.unmc.edu/AP/main.php) and a growing number
of them have also been tested against biofilms (BaAMPs database:
www.baamps.it) (Di Luca et al., 2015).
The frog skin-derived peptide temporin 1Tb (TB) is
considered a promising template for the development of next-
generation antibiotics (Di Grazia et al., 2014). It is a 13-
amino acid, mildly cationic (net charge +2) and α-helical
peptide endowed with a bacterial membrane-perturbing activity
(Mangoni et al., 2000). The peptide has previously demonstrated
a fast and potent bactericidal action particularly against Gram-
positive bacterial species, such as multidrug-resistant nosocomial
Abbreviations: AMP, antimicrobial peptide; BPM, biofilm promoting medium;
BSA, bovine serum albumin; CCS, combined consensus scale; MCC, Mathews
correlation coefficient; MOEA, multi-objective evolutional algorithms; CFU,
colony-forming units; CV, crystal violet; EDTA, ethylenediaminetetraacetic acid;
EPS, extracellular polymeric substance; FCS, fetal calf serum; FIC, fractional
inhibitory concentration; LPS, lipopolysaccharide; MBC, minimal bactericidal
concentration; MIC, minimal inhibitory concentration; PBMCs, peripheral blood
mononuclear cells; PBS, phosphate buffered saline; PI, propidium iodide; RBCs,
red blood cells; SPB, sodium-phosphate buffer; TB, temporin 1Tb; TSA, tryptone
soy agar; TSB, tryptone soy broth.
strains of Staphylococcus aureus and Enterococcus faecium
(Mangoni et al., 2008). The antibiofilm properties of TB
have been also investigated showing high activity against both
forming and mature biofilms of Staphylococcus epidermidis,
especially when the peptide was used in combination with
EDTA (Maisetta et al., 2016). Interestingly, it has been recently
reported that the peptide is able to penetrate eukaryotic cells,
kill intracellular S. aureus and promote wound-healing, further
important properties in view of a therapeutic development
(Di Grazia et al., 2014). Despite the many favorable features
of TB, the preferential spectrum of activity of the peptide
against Gram-positive bacteria partially limits its translatability
into a clinically useful agent. The rational in silico design
of novel peptides with optimized structural properties and
the chemical manipulation of existing ones represent valid
approaches to overcome the limitations of native peptides
(Maccari et al., 2013). The introduction of appropriate changes
in the peptide primary sequence and, thus, the alteration of
crucial physicochemical parameters of AMPs (e.g., cationicity,
hydrophobicity and amphipaticity) may significantly influence
their bactericidal, cytotoxic and antibiofilm potential allowing
to obtain molecules with improved antimicrobial efficacy and
broader spectrum of action (Conlon et al., 2007; Takahashi
et al., 2010; Batoni et al., 2016b). The aim of the present study
was the optimization of TB activity against both planktonic
bacteria and biofilms of medically relevant bacterial species. In
particular, the antibacterial, antibiofilm and cytotoxic properties
of TB were compared with those of two recently developed
TB analogs. The first one (TB_KKG6A), described by Avitabile
and co-workers, was initially obtained by Ala scanning on TB
sequence and further optimized by increasing its positive charge
(Avitabile et al., 2013). TB_KKG6A was found to efficiently
interact with the lipopolysaccharide (LPS) of the Gram-negative
bacterium Escherichia coli and to fold upon binding into a
bent helix (Malgieri et al., 2015). The second one (TB_L1FK),
firstly described in this study, was designed by us through
statistical-based computational strategies (Maccari et al., 2013).
Overall, TB analogs displayed a faster and stronger bactericidal
activity than the parental peptide, especially against Gram-
negative bacterial species in planktonic form. In addition, a
marked antibiofilm activity against preformed biofilms of S.
aureus and Pseudomonas aeruginosa was observed for both
TB_KKG6A and TB_L1FK used in combination with EDTA,
highlighting the potential of combinatorial drug therapies in
the management of biofilm-related infections. When assayed on
mammalian cells, TB_L1FK showed a lower cytotoxic activity
against human epithelial cells as compared to TB_KKG6A,
emerging as a promising molecule for the topical treatment of
biofilm-associated infections.
MATERIALS AND METHODS
Peptides
TB, TB_L1FK (designed as reported in “Results”) and
TB_KKG6A were synthesized by Proteogenix (Schiltigheim,
France). Analysis of the synthetic peptides by high performance
chromatography (HPLC) and mass spectrometry revealed purity
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over 98%. Peptides were diluted in milli-Q water to obtain a
stock solution of 1 mM and stored at −80◦C. The main features
of the peptides are shown in Table 1.
EDTA
Disodium ethylenediaminetetraacetic acid (EDTA) was
purchased from Sigma-Aldrich (St. Louis, USA). A stock
solution of EDTA (0.5M) was prepared in milli-Q water by
adjusting the pH to 8.0 with NaOH. The working solution
(50mM) was obtained by diluting the stock solution in milli-Q
water, sterile filtered and stored at 4◦C.
Bacterial Strains and Culture Conditions
The reference laboratory strains Klebsiella pneumoniae (ATCC
BAA-1706), P. aeruginosa (ATCC 27853), S. aureus (ATCC
33591), and S. epidermidis (ATCC 35984) were used for
the study. For the preparation of stock cultures, bacterial
strains were grown in Tryptone Soy Broth (TSB) (Oxoid,
Basingstoke, UK) until mid-log phase, subdivided in aliquots
and stored at −80◦C. For the colony-forming units (CFU)
count, serially diluted bacterial suspensions were plated on
Tryptone Soy Agar (TSA) (Oxoid) and incubated for 24 h at
37◦C.
Bactericidal Activity and Killing Kinetics in
Sodium-Phosphate Buffer
The bactericidal activity of TB, TB_L1FK and TB_KKG6A
against K. pneumoniae, P. aeruginosa, S. aureus, and S.
epidermidis was evaluated by the microdilution method in
sodium-phosphate buffer (10mM SPB, pH 7.4). Bacterial strains
were grown in TSB until exponential phase and suspended in
SPB to reach a density of 1 × 107 CFU/mL. A volume of
10µL of the bacterial suspensions was added to 90µL of SPB
containing different concentrations of the peptides (from 1.5
to 48µM). Bacteria suspended in SPB alone were used as cell
viability control. Samples were incubated at 37◦C with shaking
for various times (5, 15, 30, 60, and 90 min), subsequently
diluted 10-fold in TSB and plated on TSA to determine
the number of CFU. The minimal bactericidal concentration
(MBC) was defined as the minimal concentration of peptide
causing a reduction of at least 3 Log10 in the number of
viable bacteria after 90 min of incubation (Mangoni et al.,
2008).
Biofilm Inhibition Assay
The ability of TB, TB_L1FK, and TB_KKG6A to prevent biofilm
formation was evaluated against S. aureus and P. aeruginosa.
Bacteria were grown overnight in TSB/Glc (TSB added with
0.25% (v/v) glucose) at 37◦C. Stationary-phase cultures were
diluted 1:1,000 in Biofilm PromotingMedium (BPM; TSB diluted
1:1 with 10 mM SPB at pH 7.4 and supplemented with 0.25%
glucose). Bacterial suspensions were inoculated into flat-bottom
polystyrene 96-well microplates (Corning Costar, Lowell, USA),
in the absence (negative control) or in the presence of different
concentrations of each peptide (from 12 to 48µM). Microplates
were incubated statically at 37◦C for 24 h and biofilm biomass
was estimated by crystal violet (CV) staining assay. To this aim,
biofilms were rinsed three times with phosphate-buffer saline
(PBS), air-dried for 15 min and incubated with 0.1% (w/v)
CV (bioMérieux, Florence, Italy) for 15min. The excess of CV
was removed by washing the plates with PBS, while biofilm-
associated CV was extracted with 98% ethanol (Sigma Aldrich)
and quantified by measuring the optical density at 570 nm
(OD570) in amicroplate reader (Model 550, Bio-Rad Laboratories
Srl, Italy).
Biofilm Treatment Assay
The activity of TB, TB_L1FK, and TB_KKG6A against preformed
(24-h old) biofilms of S. aureus and P. aeruginosa was also
investigated. Briefly, biofilms were allowed to form for 24 h in
flat-bottom 96-well microplates in the absence of antimicrobial
compounds. Established biofilms were then washed three times
with PBS in order to remove non-adherent cells and incubated
in fresh BPM with different concentrations of the three peptides
(from 15 to 120µM). After 24 h of incubation, the viability of
biofilm-associated cells was evaluated by CFU counting. For this
purpose, biofilms were washed three times with PBS and bacterial
cells were detached from the surface of the wells with a pipette tip,
vigorously vortexed and plated in serial dilutions on TSA.
Evaluation of the Synergistic Effect
between TB Analogs and EDTA on
Preformed Biofilms
TB_L1FK and TB_KKG6A were combined with EDTA in order
to enhance their activity against preformed biofilms of S. aureus
and P. aeruginosa. To this aim, 24 h-old biofilms of the two
bacterial species were exposed to different concentrations of
the peptides (15 and 30µM), alone and in combination with
EDTA (1.25 and 2.5mM). Microplates were incubated statically
at 37◦C for 24 h. Following incubation, the antibiofilm effect was
evaluated in terms of number of biofilm-associated viable cells as
previously described.
TABLE 1 | Main structural and physicochemical features of the peptides used in the study.
Peptide Sequence Molecular weight Charge Hydrophobicitya
TB LLPIVGNLLKSLL-NH2 1392.78 +2 3.62
TB_L1FK FLPIVGLLKSLLK-NH2 1440.86 +3 3.43
TB_KKG6A KKLLPIVANLLKSLL-NH2 1663.15 +4 1.91
aHydrophobicity was calculated with the combined consensus scale (CCS) through the BaAMPs database (Di Luca et al., 2015).
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Evaluation of the Synergistic Effect
Between TB Analogs and EDTA on
Planktonic Bacteria in Biofilm-Like
Conditions
The antibacterial activity of TB_L1FK and TB_KKG6A, used
alone and in combination with EDTA, was also tested
against planktonic cells of S. aureus and P. aeruginosa. The
Minimal Inhibitory Concentration (MIC) of the peptides, EDTA
and the peptide-EDTA combinations was determined by the
microdilution method under the same experimental conditions
used for the biofilm assay. Briefly, bacteria from overnight
cultures were diluted 1:1,000 in BPM and incubated for 24 h
at 37◦C in propylene tubes in the presence of TB_L1FK and
TB_KKG6A (from 3.75 to 120µM), alone and combined with
EDTA (from 0.3 to 10mM). MIC was defined as the lowest
concentration of the compounds resulting in the complete
inhibition of visible growth. The effect of each combination on
cell growth was studied using an adapted Fractional Inhibitory
Concentration (FIC) index analysis. FIC index was calculated as
follows: 6 (FICA + FICB), where FICA is the MIC of compound
A in combination/MIC of compound A alone, and FICB is the
MIC of compound B in combination/MIC of compound B alone.
Synergism was defined as a FIC index≤ 0.5, indifference as a FIC
index> 0.5 and antagonism as a FIC index> 4 (Katragkou et al.,
2015; Dosler et al., 2016).
Hemolysis Assay
Hemolytic activity of TB and its analogs was tested against human
red blood cells (RBCs) as previously described (Tavanti et al.,
2011). Briefly, peripheral blood obtained from healthy donors
was centrifuged (1,000 × g for 10 min, 4◦C) and washed three
times with PBS (Euroclone, Milan, Italy). A suspension of RBCs
(4%, v/v) was mixed with various concentrations of the peptides
(from 12 to 96 µM) into a round-bottom polystyrene 96-well
microplate (Corning Costar). RBCs suspended in PBS alone
were used as negative control (0% hemolysis), while cells lysed
with 0.1% Triton X-100 were taken as positive control (100%
hemolysis). The microplate was incubated for 1 h at 37◦C and
then centrifuged at 1,000 × g for 20 min, 4◦C. Supernatants
were transferred to a new plate and the optical density at 450
nm (OD450) was measured by means of a microplate reader.
The hemolytic activity was quantified according to the following
formula: hemolysis (%) = [(OD peptide – OD negative control)/(OD
positive control – OD negative control)]× 100.
Cytotoxicity Assay
Cytotoxic activity of the peptides was assessed against human
peripheral blood mononuclear cells (PBMCs) and human non-
small-cell lung adenocarcinoma A549 cells (ATCC CCL-185).
PBMCs were isolated from buffy coats by conventional density
gradient centrifugation. For this purpose, buffy coats were
diluted 1:1 in PBS supplemented with 10% (v/v) sodium citrate
(Sigma-Aldrich) and layered on Lympholyte-H gradient medium
(Euroclone). Following centrifugation at 200 × g for 20 min at
room temperature, the supernatant was eliminated in order to
remove platelets. Buffy coats were further centrifuged at 800 × g
for 20 min at room temperature and the lymphocyte/monocyte
layer was harvested at the sample/medium interface. PBMCs
were washed three times with PBS containing 0.5% (wt/v) bovine
serum albumin (BSA; Sigma-Aldrich) and 10% sodium citrate,
counted and re-suspended in RPMI 1640 (Euroclone) added
with 10% (v/v) fetal calf serum (FCS; Euroclone) and 2mM L-
glutamine. Cells (1 × 105 per well) were seeded into round-
bottom 96-well microplates (Corning Costar) and incubated with
increasing concentrations of the peptides (from 12 to 96µM)
for 24 h at 37◦C, 5% CO2. PBMCs incubated with culture
medium were used as negative (cell viability) control, while
cells treated with cycloheximide (2mg/mL) served as a positive
(death) control.
A549 cells were grown in tissue culture flasks in Dulbecco’s
modified Eagle’s medium (DMEM; Euroclone) containing 10%
FCS and 2mM L-glutamine. Confluent monolayers of A549 cells
were washed with PBS, treated with a trypsin-EDTA solution
(Sigma-Aldrich), centrifuged at 300 × g for 10min, counted
and re-suspended in complete DMEM at a final density of 5 ×
104 cells/mL. A volume of 200µL of the cell suspension was
seeded into flat-bottom 96-well microplates (Corning Costar)
and cultured for 24 h at 37◦C, 5% CO2. Peptides at a final
concentration of 12–96µMwere added to the cells and incubated
for further 24 h at 37◦C, 5% CO2. A549 cells incubated with
culture medium were used as negative (cell viability) control,
while cells treated with cycloheximide (2 mg/mL) served as a
positive (death) control.
Cytotoxic activity was evaluated by the propidium iodide
(PI) flow cytometric assay. To this end, PBMCs were washed
once in PBS, resuspended in 100µL, and incubated with 5µL
of a PI solution (50µg/mL) (Sigma-Aldrich) for 4 min in the
dark. Similarly, A549 cells were harvested by trypsinization,
rinsed once with PBS and exposed to PI. Counting of viable
(PI-negative) and dead (PI-positive) cells was carried out with
a BD Accuri C6 flow cytometer (BD Biosciences, Mountain
View, CA) and data were analyzed using BD Accuri C6
software (BD Biosciences). Cytotoxic effect was determined
according to the following formula: Cytotoxicity (%) = [(PI-
positive cells peptide – PI-positive cells negative control)/(100 – PI-
positive cells negative control)] × 100. The IC50 values (Inhibitory
Concentration) were defined as the concentration of the
peptides causing 50% cell death as compared to the untreated
control.
Statistical Analysis
All the experiments were performed at least in triplicate, unless
otherwise specified. Differences between mean values of groups
were evaluated by one-way analysis of variance (ANOVA)
followed by Tukey-Kramer post-hoc test, after normalization
of the data. A p-value < 0.05 was considered statistically
significant.
RESULTS
TB_L1FK design
In order to improve the therapeutic potential of TB, a
novel peptide was computationally designed starting from TB
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sequence. In a previous work, chemophysical analysis of known
AMPs sequences was successfully employed to design a statistical
model of membrane-disrupting peptides able to account for non-
natural amino acids (Maccari et al., 2013). In this work, an
additional statistical model was designed to account for peptides’
cytotoxic effect. Together with the previously described models
for the secondary structure and the antimicrobial activity, a forth
constraint was imposed in order to retain as much as possible
the sequence similarity with TB. A dataset of peptides with
proved cytotoxic effect was appositely designed by collecting
and combining data from different bioactive peptide databases
(Gupta et al., 2013). Furthermore, another set of peptides
was designed to represent non-cytotoxic peptides, allowing the
statistical model to grasp the features that distinguish the two
sets (see Section 1.1 in the Supplementary Material). A number
of filters aimed to normalize and uniform the training set of
peptides were applied and then, sequences were encoded into
physicochemical variables representing global and topological
properties of peptides. A machine learning algorithm was
adopted to build a prediction engine able to discern between
toxic and non-toxic peptides (see the Supplementary Material
for details in model training and validation). Model performance
was evaluated by the Mathews Correlation Coefficient (MCC),
which assesses the prediction in terms of true and false positives
and negatives. In the final configuration, a prediction model
with an MCC value of 0.82 was obtained. The candidate
sequence, named TB_L1FK, was designed by applying the
statistical model to a particular class of Genetic Algorithms, called
Multi-Objective Evolutional Algorithms (MOEA) that allows
to screen for candidates that simultaneously satisfy different
criterions.
As reported in Figure 1, that shows a predictive simulation
of the structure of TB and its two analogs, TB_L1FK displays
similar physicochemical characteristics to the parental peptide.
Hydrophobicity and net charge of TB_L1FK are close to those
of TB, while TB_KKG6A presents a different hydrophobic
profile and an increased net charge, particularly localized at
the C-terminus. One of the aims in the computational design
of TB_L1FK was to retain all the features that could infer
in the membrane interaction of the peptide with the target
cells. Besides, molecular hydrophobicity and net charge, as
well as size and molecular weight, represent important aspects
for the loading and the controlled release of peptides such
as TB from nanostructured delivery systems (Piras et al.,
2015).
Bactericidal Activity and Killing Kinetics of
Peptides in Sodium-Phosphate Buffer
The antimicrobial activity of TB, TB_KKG6A, and TB_L1FK
was evaluated in terms of MBC values toward S. aureus
and S. epidermidis as models of Gram-positive bacteria and
against K. pneumoniae and P. aeruginosa as models of Gram-
negative bacteria. As shown in Table 2, TB was mainly active
against Gram-positive bacteria and exhibited a bactericidal effect
against Gram-negative bacteria only at 48µM. Both analogs
displayed a markedly increased activity compared to the parental
peptide against all the bacterial species tested, but especially
against the Gram-negative ones. In particular, a 2- to 8-fold
reduction in the MBC compared to TB was observed against
the Gram-positive bacteria, while an up to 16-fold decrease in
the MBC value was observed in the case of the Gram-negative
bacteria.
Time-kill studies on two representative bacterial species,
S. aureus and P. aeruginosa, were carried out using the
peptides at concentrations equal to their MBC. TB exerted its
bactericidal activity toward S. aureus after approximately 90
min of incubation (Figure 2A). Both TB_L1FK and TB_KKG6A
exhibited a faster killing kinetics than TB against the same
bacterial species causing a reduction of at least 3 Log10
in the number of viable bacteria within 30 and 60 min,
respectively (Figure 2A). All three peptides showed a more
rapid bactericidal effect against P. aeruginosa than against S.
aureus (Figure 2B). In particular, TB and TB_KKG6A showed
similar killing kinetics, being bactericidal after 15 min of
incubation, while the most rapid bactericidal effect was exerted
by TB_L1FK that determined the complete eradication of the
starting bacterial inoculum within as little as 5 min of incubation
(Figure 2B).
Effect of TB and TB Analogs on Forming
and Preformed Biofilms
We first investigated the ability of TB, TB_L1FK and TB_KKG6A
to inhibit the formation of biofilms of S. aureus and P. aeruginosa,
two bacterial species often involved in the formation of biofilms
particularly refractory to antimicrobial treatment. The inhibitory
effect was assessed by CV staining (total biofilm biomass)
evaluating the percentage of biofilm formation after 24 h of
incubation with TB or the two TB analogs, as compared to the
control biofilms (cells incubated in medium only). As shown in
Figure 3A, differently from the parental peptide, TB_L1FK and
TB_KKG6A reduced the ability of S. aureus to form biofilm of
more than 50% as compared to the untreated control at 12µM.
All the peptides caused around 80% decrease of the biofilm
biomass at the concentration of 24µM. When the peptides were
assayed against forming biofilms of P. aeruginosa, no inhibitory
activity of TB and TB_L1FK was observed at concentrations
up to 48µM (Figure 3B). In contrast, TB_KKG6A displayed a
considerable ability in reducing the biomass of P. aeruginosa
biofilms, causing an 80% inhibition at the concentration of
24µM (Figure 3B).
Secondly, the efficacy of TB and its analogs against preformed
(24 h-old) biofilms of S. aureus and P. aeruginosa was evaluated
by CFU counting after 24 h of incubation with the peptides. In
the case of S. aureus biofilms, TB did not exert a considerable
antibiofilm activity at concentrations up to 120µM (data not
shown), while TB_L1FK and TB_KKG6A caused a decrease of
approximately 2 Log10 in the number of biofilm-associated viable
cells as compared to untreated biofilms at 30µM (Figures 4A,B).
When tested against biofilms of P. aeruginosa, none of the three
peptides displayed a significant ability to reduce the number
of CFU at the highest tested concentration (120µM) (data not
shown).
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FIGURE 1 | Predictive simulations of hydrophobic profile and 3D structure of TB (A), TB_L1FK (B), and TB_KKG6A (C). The hydrophobic profile calculated
with the combined consensus scale (CCS) is schematized on the left side (Maccari et al., 2013). 3D structures (right side of the figure) were calculated with
PEP-FOLD3 (Lamiable et al., 2016); the distribution of hydrophobic and charged residues is highlighted.
Effect of TB Analogs, alone and in
Combination with EDTA, on Preformed
Biofilms
The possibility to improve the activity of TB analogs against
preformed biofilms of S. aureus and P. aeruginosa was
investigated combining the peptides with EDTA, a chelating
agent previously reported to enhance the antibiofilm properties
of TB (Maisetta et al., 2016). Indeed, the ability of EDTA
to establish strong complexes with divalent cations essential
for matrix stability could produce a matrix-disaggregating
effect and promote the accessibility of peptides to biofilm-
forming cells. The antibiofilm activity of various peptide-EDTA
combinations was evaluated by CFU counting. Among all
the tested combinations, the most powerful potentiating effect
in terms of viable count reduction was obtained using both
peptides at the concentration of 30µM in combination with
1.25mM (for S. aureus) or 2.5mM EDTA (for P. aeruginosa).
As regards S. aureus (Figures 4A,B), the combination of both
TB_L1FK and TB_KKG6A with EDTA caused a reduction in
the CFU number of approximately 1 Log10 (90%) compared
to the peptides and EDTA used alone, and 3 Log10 (99.9%)
compared to control biofilms after 24 h of incubation. Also
in the case of P. aeruginosa, an enhanced ability of TB_L1FK
and TB_KKG6A in biofilm reduction was demonstrated when
peptides were used in combination with EDTA. Indeed, both
peptide-EDTA combinations reduced the CFU number of
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TABLE 2 | MBCs of TB, TB_L1FK, and TB_KKG6A against Gram-positive
and Gram-negative bacteria in sodium-phosphate buffer (10 mM SPB, pH
7.4).
Gram-positive Gram-negative
S. aureus
ATCC
33591
S. epidermidis
ATCC 35984
K. pneumoniae
ATCC
BAA-1706
P. aeruginosa
ATCC 27853
TB 12a 6 48 48
TB_L1FK 6 1.5 6 6
TB_KKG6A 1.5 1.5 3 3
aNumbers represent the MBC values expressed in µM.
approximately 1 Log10 as compared to the peptide used alone
(Figures 4C,D).
Effect of TB Analogs, alone and in
Combination with EDTA, on Planktonic
Bacteria in Biofilm-Like Conditions
In order to investigate whether the synergism between TB
analogs and EDTA was due to a disaggregating effect on biofilm
extracellular matrix and/or to a direct effect on bacterial cells, we
assessed the activity of the combination on planktonic bacteria in
biofilm-like conditions (i.e., stationary phase cells suspended in
BPM) in terms of MIC values. As shown in Table 3, when tested
alone, TB_L1FK displayed MICs of 15 and 120µM against S.
aureus and P. aeruginosa, respectively. In the case of TB_KKG6A,
the growth-inhibiting effect was recorded at 7.5µM for S.
aureus and at 30µM for P. aeruginosa. In order to identify
any synergistic interaction, sub-inhibitory concentrations of each
peptide and EDTA were combined and the FIC index for the
different peptide-EDTA combinations was calculated. Differently
to what observed for the biofilm mode of growth, EDTA was
not able to potentiate the antibacterial activity of TB_L1FK and
TB_KKG6A against planktonic cells of S. aureus (FIC index
> 0.5, Table 3). Conversely, a synergistic effect between both
TB analogs and EDTA was observed against P. aeruginosa
planktonic cultures (FIC index = 0.25, Table 3). Interestingly,
the combination with EDTA produced an 8-fold decrease in the
MIC of both peptides against planktonic P. aeruginosa grown
in biofilm-like conditions, suggesting a direct effect of EDTA
in displacing divalent cations that are required for the integrity
of the outer membrane of Gram-negative bacteria (Gray and
Wilkinson, 1965; Asbell and Eagon, 1966).
Hemolytic Activity
The hemolytic activity of TB and TB analogs was evaluated
toward human RBCs. As shown in Figure 5, no hemolytic effect
of the parental peptide was assessed at concentrations up to
96µM. An overall increase in hemolytic activity of both analogs
was observed. Nevertheless, a hemolysis below 10%, commonly
recognized as a safe cut-off (Amin and Dannenfelser, 2006), was
observed at concentrations up to 24µM of TB_KKG6A and up
to 48µM of TB_L1FK.
Cytotoxicity against PBMCs and A549 Cells
TB, TB_L1FK and TB_KKG6A were tested for cytotoxic activity
on PBMCs and A549 cells by flow cytometric determination of
PI incorporation in cells treated with different concentrations of
the three peptides. As shown in Figure 6, TB did not exhibit a
significant cytotoxic effect toward both PBMCs and A549 cells
at any of the tested concentrations. Indeed, an approximately
90% viability was observed at 96µM for both cell types. Both
TB analogs displayed higher cytotoxicity against both cell types
as compared to TB (Figures 6A,B). When the toxic effect was
evaluated as IC50 value, TB_L1FK and TB_KKG6A showed
comparable levels of cytotoxicity against PBMCs (IC50 values
of 52 and 49µM, respectively). In contrast, TB_L1FK displayed
lower levels of cytotoxicity against A549 cells with an IC50 value
of 59 vs. 16µM of TB_KKG6A.
DISCUSSION
The use of AMPs as an alternative to conventional antimicrobial
agents in the treatment of antibiotic-resistant and/or biofilm-
associated infections represents a possibility that is increasingly
taken into consideration. Over the last years, a growing body
of research has focused on frog skin-derived AMPs with
considerable attention being devoted to the antibacterial activity
and the mechanism of action of TB (Conlon et al., 2014; Mangoni
et al., 2016). It has emerged that such a peptide possesses
significant membrane-perturbing properties and folds in a α-
helix upon interaction with bacterial membranes (Mangoni et al.,
2000). Like most of the members of the temporin family, TB is
considerably effective against Gram-positive bacteria, including
clinically important multidrug-resistant pathogens, but only
poorly active against Gram-negative bacteria (Mangoni et al.,
2008). The lower level of activity of TB against these bacteria is
likely due to the presence of LPS that induces the oligomerization
of the peptide, and hence prevents it to diffuse through the
cell wall and reach the target cytoplasmic membrane (Rosenfeld
et al., 2006; Mangoni and Shai, 2009). Design of TB analogs
with modification of the peptide primary structure may provide
peptides with stronger activity against Gram-negative bacterial
species and increase the translational potential of TB. Computer-
assisted design strategies have led us to obtain TB_L1FK, in which
the leucine in position 1 has been replaced by a phenylalanine,
the asparagine 7 has been eliminated and an extra lysine has
been inserted at the C-terminus increasing the net charge
of the peptide. Differently from the traditional optimization
procedures, the computational method employed herein allowed
to predict the effect of multiple amino acid positions on the
antibacterial activity and cytotoxicity of TB, thereby enabling to
improve different features of the peptide at the same time and to
design a set of candidates for experimental validation. The other
analog analyzed in this work, i.e., TB_KKG6A, has been designed
by Avitabile and colleagues by replacing the glycine in position
6 with an alanine according to the Ala-scanning method and by
adding two lysines at the N-terminus in order to produce a more
cationic peptide (Avitabile et al., 2013). Circular dichroism and
NMR studies have previously shown that TB_KKG6A strongly
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FIGURE 2 | Killing kinetics of TB, TB_L1FK, and TB_KKG6A against S. aureus ATCC 33591 (A) and P. aeruginosa ATCC 27853 (B). Bacteria were incubated
in sodium-phosphate buffer (10mM SPB, pH 7.4) with the peptides at concentrations equal to their MBCs for various times. Control (CTRL) represents untreated
bacteria. Solid line indicates a reduction of ≥3 Log10 in the number of control bacteria at each time of incubation. A number of 10 CFU/mL was taken as detection
limit. Data are expressed as mean ± standard error of at least three independent experiments.
FIGURE 3 | Inhibitory effect of TB, TB_L1FK, and TB_KKG6A on biofilm formation of S. aureus ATCC 33591 (A) and P. aeruginosa ATCC 27853 (B). The
inhibitory effect was assessed by measuring the total biofilm biomass by crystal violet staining after 24 h of incubation with the peptides. Control (CTRL) represents
untreated bacteria. Dashed and solid lines represent 50 and 80% reduction in biofilm biomass as compared to untreated controls, respectively. Data are reported as
mean ± standard error of at least three independent experiments.
interacts with the LPS of the Gram-negative bacterium E. coli
and assumes a bent helical conformation upon binding (Avitabile
et al., 2013; Malgieri et al., 2015).
A comparative analysis of the properties of TB and these
two analogs was performed starting from the evaluation of
their bactericidal activity against multidrug-resistant bacteria
in planktonic form. TB_L1FK and TB_KKG6A displayed an
expanded spectrum of action as compared to the parental
peptide, being active against all the tested Gram-positive and
Gram-negative bacterial strains at very low concentrations. It is
likely that the presence of additional positively charged amino
acids in their sequence enhanced the affinity of the analogs
toward Gram-negative bacteria. This observation is consistent
with previous studies, in which optimized analogs of both TB
and other temporins (Conlon et al., 2007; Capparelli et al.,
2009; Srivastava and Ghosh, 2013) were obtained through
the introduction of extra positive charges. Cationic amino
acids, such as lysine, play a key role in the interaction
of AMPs with the negatively charged components of the
bacterial cell surface and the cytoplasmic membrane (Shai,
1999; Hancock and Sahl, 2006). Therefore, an increase in
peptide cationicity can promote a more efficient interaction
with bacteria, and hence a stronger antibacterial activity (Han
et al., 2016). Moreover, faster killing kinetics were observed
for the analogs compared to TB against both S. aureus
and P. aeruginosa, selected as representative Gram-positive
and Gram-negative bacterial species, respectively. The short
time required for peptides to exert their bactericidal effect
correlates with the bacterial membrane-permeabilizing activity
of the temporin family (Mangoni et al., 2000; Saviello et al.,
2010).
The three peptides were also compared regarding their
antibiofilm properties using reference strains of S. aureus and
P. aeruginosa. Biofilm-related infections currently represent a
relevant clinical problem because of the intrinsic recalcitrance of
biofilms to the antibiotic therapy. S. aureus and P. aeruginosa
are common bacterial species involved in biofilm-associated
infections, such as wound infections, lung infections in cystic
fibrosis patients and implant-related infections (e.g., central
venous catheters, endotracheal tubes, prostheses; Ciofu et al.,
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FIGURE 4 | Activity of TB_L1FK and TB_KKG6A, used alone and in combination with EDTA, against preformed (24-h old) biofilms of S. aureus ATCC
33591 (A,B) and P. aeruginosa ATCC 27853 (C,D). The antibiofilm activity of the peptides, EDTA and the peptide-EDTA combinations was evaluated by CFU counting
after 24 h of incubation. Control (CTRL) represents untreated biofilms. Data are reported as mean ± standard error of at least three independent experiments.
*p < 0.05; **p < 0.01; ***p < 0.001 (one way ANOVA followed by Tukey-Kramer post-hoc test).
TABLE 3 | MICs of TB_L1FK and TB_KKG6A in biofilm-like conditions
against S. aureus and P. aeruginosa and FIC index of the peptide-EDTA
combinations.
S. aureus ATCC 33591 P. aeruginosa ATCC 27853
TB_L1FK TB_KKG6A TB_L1FK TB_KKG6A
MICa 15 7.5 120 30
FIC index >0.5 >0.5 0.25 (15µM)b 0.25 (3.75µM)
aConcentrations are expressed in µM.
bParentheses include the concentration of the peptide resulting in a synergistic effect.
2015). The ability of these pathogens to produce biofilms is
responsible for the establishment of chronic infections, thereby
constituting a primary impediment to the complete recovery
from infectious diseases (Costerton et al., 1999; Dean et al., 2011).
Thus, the identification of new broad-spectrum antibiofilm
agents and innovative therapeutic strategies appears as a growing
need. To this aim, we explored the efficacy of TB and TB analogs
both in preventing biofilm formation and in treating mature
biofilms and attempted to enhance the antibiofilm activity of
the peptides by combining them with adjuvant compounds. TB
analogs showed an improved ability to inhibit the formation of
S. aureus biofilms at 12µM, while at 24µM all three peptides
were equally active, causing more than 80% reduction of the
biofilm biomass. TB_KKG6A, but not TB_L1FK, showed also a
marked activity in inhibiting biofilm formation of P. aeruginosa
at the concentration of 24µM. In all cases, the inhibitory activity
of the peptides was observed at concentrations close to the
MIC values determined in biofilm-like conditions (Table 3),
suggesting that the antibiofilm effect was due to the direct killing
of biofilm-forming bacteria at their planktonic stage rather than
to biofilm-specific mechanisms (Segev-Zarko et al., 2015; Batoni
et al., 2016a). When assayed against preformed biofilms, the two
analogs, differently from TB, were able to significantly reduce
the number of biofilm-associated cells of S. aureus at 30µM,
while none of the peptides was effective against P. aeruginosa
even at 120µM. It is commonly recognized that preformed
biofilms are more challenging to target than the early stages of
biofilm formation. The reduced susceptibility of mature biofilms
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FIGURE 5 | Hemolytic activity of TB, TB_L1FK, and TB_KKG6A on
human erythrocytes after 1 h of incubation at 37◦C. The hemolytic
activity was evaluated by the spectrophotometric determination of hemoglobin
released from erythrocytes. PBS (0% hemolysis) and Triton X-100 (100%
hemolysis) were used as controls. Hemolysis values ≤10% (dashed line) are
considered to be non-hemolytic (Amin and Dannenfelser, 2006). Data are
reported as mean ± standard error of three independent experiments.
to AMPs is mainly due to the presence of the extracellular
matrix that surrounds the bacterial population and constitutes
an actual impediment to peptide penetration into the biofilm
structure (Otto, 2006; Batoni et al., 2016a). Cationic peptides
can be repulsed or sequestrated by the biofilm extracellular
polymeric molecules, especially exopolysaccharides and DNA,
so that their interaction with bacterial cells can be significantly
hampered (Batoni et al., 2016a). In particular, the polysaccharide
intracellular adhesin (PIA) of staphylococcal biofilm matrix and
alginate, Pel and Psl polysaccharides of P. aeruginosa biofilms
have been demonstrated to play a major role in the protection
from AMPs (Vuong et al., 2004; Chan et al., 2005). Thus, the use
of AMPs in combination with compounds able to disaggregate
the extracellular matrix could represent a promising strategy to
increase their antibiofilm activity and therapeutic potential. In
this regard, the chelator EDTA has been shown to reduce the
structural integrity of the biofilm of several bacterial species by
forming strong complexes with divalent cations (magnesium,
calcium, iron) essential for matrix stability (Percival et al., 2005;
Banin et al., 2006; Cavaliere et al., 2014; Maisetta et al., 2016).
Herein, we combined TB analogs with EDTA in order to improve
their efficacy against preformed biofilms of S. aureus and P.
aeruginosa. The combination of TB_L1FK and TB_KKG6A with
EDTA resulted in a potentiated antibiofilm effect that led to
a statistically significant reduction in the viable count of both
bacterial species at a peptide concentration of 30µM. In order
to prove that the enhancement of the antibiofilm activity of TB
analogs was actually due to the destabilizing action of EDTA on
the biofilmmatrix, we also evaluated the effect of the combination
peptide-EDTA on planktonic cells in biofilm-like conditions.
Interestingly, the peptides exhibited synergy with EDTA against
planktonic cultures of P. aeruginosa, but not against S. aureus.
The combination treatment inhibited the growth of P. aeruginosa
to a greater extent than the peptide used alone, suggesting a
direct effect of EDTA also on planktonic bacteria. It is known that
divalent cations are key elements in maintaining the integrity of
the outer membrane of Gram-negative bacteria as they attenuate
the electrostatic repulsive forces between adjacent LPS molecules
by forming salt bridges (Gray and Wilkinson, 1965; Asbell and
Eagon, 1966). Therefore, chelation of divalent cations by EDTA
could enhance the action of the tested AMPs by destabilizing the
outer membrane and thus facilitating the peptide access to the
bacterial inner membrane. Furthermore, the chelating activity
of EDTA may contribute to remove the cationic barrier that
prevents the electrostatic interaction of cationic AMPs with the
negatively charged bacterial surface (Walkenhorst et al., 2014).
Thus, it is likely that EDTA mainly acted as an extracellular
matrix-disaggregating agent in the case of S. aureus biofilms,
facilitating the diffusion of the peptides through the biofilm
layers. On the other hand, in the case of P. aeruginosa biofilms,
the enhanced effect of the peptide-EDTA combinations could be
very well due not only to the perturbing effect on the extracellular
matrix, but also on a direct effect on biofilm-embedded cells.
The evaluation of the cytotoxicity of AMPs toward the
host cells is an essential step to their development as
therapeutics. It is generally accepted that there is a direct
relationship between the antimicrobial potency of AMPs and
their cytotoxic properties (Takahashi et al., 2010). A subtle
balance of several physicochemical and structural parameters
(cationicity, amphipathicity, hydrophobicity, and helicity) is
necessary to ensure themaximum antibacterial efficacy and target
cell selectivity of the peptides (Chen et al., 2005; Zelezetsky
et al., 2005). Therefore, we evaluated the hemolytic effect of
TB analogs on human erythrocytes and their cytotoxic activity
on human PBMCs and the human-derived epithelial cell line
A549. Along with the enhancement of the antimicrobial activity,
modifications in TB sequence led to an overall increase of
the hemolytic activity and cytotoxicity of the native peptide.
Nevertheless, both TB_L1FK and TB_KKG6A were non-
hemolytic at concentrations that resulted to be active against
both planktonic and biofilm-growing bacteria. A percentage of
hemolysis lower than 10% was assessed at peptide concentrations
close to that used in combination with EDTA in treating
mature biofilms of S. aureus and P. aeruginosa. When tested
against mammalian cells, TB_L1FK resulted less cytotoxic than
TB_KKG6A against human epithelial cells, suggesting that the
computational method employed generated a sequence showing
a good compromise between antibacterial and cytotoxic activity
and promising features for topic applications. In the case of
PBMCs, both TB analogs displayed comparable and quite high
levels of cytotoxicity. A promising solution to reduce the toxicity
of AMPs is the development of appropriate delivery systems for
their controlled and/or targeted release. In this regard, our group
has recently developed a chitosan-based nanostructured delivery
system loaded with TB that ensured a considerable reduction
of the cytotoxic activity of the peptide toward mammalian cells
(Piras et al., 2015).
CONCLUSIONS
In the present study, we performed a detailed characterization
of the bactericidal and antibiofilm activity of TB analogs in
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FIGURE 6 | Cytotoxicity of TB, TB_L1FK, and TB_KKG6A on human PBMCs (A) and A549 cells (B) after 24 h of incubation at 37◦C, 5% CO2. The cytotoxic
activity was evaluated by the PI flow cytometric assay. Cells incubated with culture medium only (100% cell viability) and cells treated with cycloheximide (0% cell
viability) were used as controls. Data are reported as mean ± standard error of three independent experiments.
order to demonstrate the potential of computational peptide
design in the improvement of the antimicrobial properties
of AMPs. The introduction of appropriate modifications in
the primary sequence of TB led to optimized analogs with a
stronger and faster bactericidal activity and a wider spectrum
of action as compared to the parental peptide. Furthermore, TB
analogs exhibited an improved ability both in preventing biofilm
formation and in treating preformed biofilms of S. aureus and
P. aeruginosa, especially when used in combination with EDTA.
The antibiofilm action of the peptide-EDTA combination was
likely due to a disaggregating effect on the biofilm extracellular
matrix and/or to a direct effect on bacterial cells. Collectively, our
results suggest that TB analogs represent a promising template
for the development of novel antimicrobials for the treatment
of antibiotic-resistant and/or biofilm-associated infections. In
this regard, current work is devoted to the development of a
nanostructured delivery system for TB analogs with the aim to
reduce their toxicity and to control their pharmacokinetics, thus
further improving the therapeutic potential of these molecules.
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